

**PRESENTING A PRESCRIPTION
AIMED AT GROWTH.**



PRESENTING

ICICI Prudential
**Nifty Pharma
Index Fund**

NFO Dates

Opens: 25th November 2022

Closes: 9th December 2022

 **ICICI**
PRUDENTIAL 
MUTUAL FUND

TARAKKI KAREIN!

The industry includes generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics.

India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports.

70% of WHO's vaccines (as per the essential Immunization schedule) are sourced from India.

The medical devices market in India has the potential to grow ~4x the current market size by FY 2030, backed by growing healthcare needs and government's commitment to facilitate growth.

3rd largest industry worldwide in terms of production by volume and 14th by value.



Current contribution to country's GDP is 1.72%.

Second highest number of US FDA approved plants outside the US.



Largest provider of generic drugs globally.

Current market size of the medical devices sector is estimated to be US\$ 11 bn –
1.5% of the global market.

An overall increase of 7.95% in budget allocation for Health Schemes in 2021-22 as
compared to allocation in 2020-21.



Note: *Top 10 companies as per research by HDFC Securities



Government Expenditure on Health in India (US\$ billion)

Legend: FY16 (lightest), FY17, FY18, FY19, FY20 (darkest)




Pradhan Mantri Bhartiya
Janaushadhi Pariyojana (PMBJP)




Covid Beep




National Health Policy

Composition of Indian Pharmaceutical Exports



Concentration of exports in drug formulations and biological facilitates production processes across the world and also contributes to the supply of final products in the form of generics.

Indian Pharmaceutical Market



Source: India Brand Equity Foundation

India's domestic pharmaceutical market is likely to grow to US\$65 billion by 2024 and further expected to reach US\$130 billion by 2030.



Government Support – As per the Union Budget 2022-23, US\$ 4.83 billion has been allocated to the 'National Health Mission'.



Medical tourism – Quality services at marginal costs compared to US, Europe and South Asia.



Skilled drug manufacturing - Low cost generic patented drugs as well as end-to-end manufacturing.



High domestic demand - Launch of one of the largest National Health Protection Schemes globally.


ICICI Prudential Nifty Pharma Index Fund (The Scheme)

An open-ended Index scheme replicating Nifty Pharma Index

INVESTS
IN

Nifty Pharma Index (Underlying Index)

The Index is designed to reflect the behavior and performance of the companies that are engaged into manufacturing of pharmaceuticals and biotechnology companies.



Nifty Pharma Index

Top 10 Holdings (%)




Quantitative Indicators	P/E Ratio	P/B Ratio	Dividend Yield
Nifty Pharma Index	37.11	4.52	0.99
Nifty 50 Index	21.42	4.23	1.25

Standard Deviation %	1 Year	5 Year	Since Inception
Nifty Pharma Index	17.22	21.83	20.40
Nifty 50 Index	18.04	19.38	23.48

Above index constituents and statistics are as of October 31, 2022. Data source: www.nseindia.com. The sector(s)/stock(s) mentioned in this document do not constitute any recommendation of the same and ICICI Prudential Mutual Fund may or may not have any future positions in the sector(s)/stock(s).

Nifty Pharma Index has grown at 9.52% annually since October 2012. Rs.1,00,000 invested in Nifty Pharma Index in 2012 would be worth Rs. 2,48,220 by end of October 2022.


10 Year Performance



Performance of the Index : Calendar Year Returns (%)



Nifty Pharma TRI has outperformed Nifty 50 TRI 5 times till 31st October 2022




Data as on 31st October 2022. Data source: MFI Explorer. MFI Explorer is a tool provided by ICRA Online Ltd. For their standard disclaimer please visit <http://www.icraonline.com/legal/standard-disclaimer.html>. Past performance may or may not be sustained in the future. The Total Return Variant of the Index has been used. The performance figures of the Index do not indicate the returns/performance of the Scheme. CY Returns for 2022 are Year to date.

Performance of the Index : CAGR (%)



CAGR (%)



	1 Month	3 Months	6 Months	1 Year	3 Years	5 Years
■ Nifty 50 TRI	8.2	4.14	14.71	4.07	16.85	13.6
■ Nifty Pharma TRI	1.48	0.15	4.19	-4.35	19.53	7.67


Data as 31st October 2022. Data source: MFI. MFI Explorer is a tool provided by ICRA Online Ltd. For their standard disclaimer please visit <http://www.icraonline.com/legal/standard-disclaimer.html>
 Past performance may or may not be sustained in the future. The Total return variant of the Index has been used. Returns more than 1 year are CAGR. The performance of the index does not signify performance of the scheme.

Since 31-October-2012
(First Observation on 31-October-2002) till 31-October-2022

10 Years Rolling Returns

	Nifty 50 TRI	Nifty Pharma TRI
Minimum	-8.30	-8.93
Maximum	6.62	5.12
Average	0.06	0.05

Taking SIP amount as Rs.10,000



Data as on 31st October 2022. Returns are in XIRR %.Source MFIE. Returns are in Percentage terms. Past performance may or may not be sustained in future. The above calculation is considering the SIP date as beginning of each month. The Total Return Variant of the Index has been used. The performance figures pertain to the Index and do not in any manner indicate the returns/performance of the Scheme Source.

Why invest in ICICI Prudential Nifty Pharma Index Fund?




COST EFFICIENCY:

Low cost of production and R&D boosts efficiency, leading to competitive exports.



ECONOMIC DRIVERS:

High economic growth along with increasing penetration of health insurance to push expenditure on healthcare and medicine.



CHANGING PREFERENCES:

Greater awareness, changing attitude towards preventive healthcare, increased precedence of lifestyle diseases and better access to insurance will further boost the industry.



FDI POLICY:

Up to 100% and 74% FDI allowed for Greenfield and Brownfield pharmaceuticals projects respectively through automatic route.



INCREASING INVESTMENT:

The Indian drugs and pharmaceuticals sector received cumulative FDIs worth US\$ 19.41 billion between April 2000-March 2022.

Scheme Name NFO Period	ICICI Prudential Nifty Pharma Index Fund 25th November, 2022 to 9th December 2022
Scheme Type	An open ended index scheme replicating Nifty Pharma Index
Plans/ Options	Plans: Regular & Direct Options: Growth & IDCW (IDCW Payout & IDCW Reinvestment)
Exit Load	Nil The Trustees shall have a right to prescribe or modify the exit load structure with prospective effect subject to a maximum prescribed under the Regulations.
Minimum Application Amount, including switches	DURING NEW FUND OFFER PERIOD/ DURING ONGOING OFFER PERIOD: Rs.1000/- (plus in multiple of Re.1) Minimum application amount for switch-ins: Rs. 1000/- and any amount thereafter.
Minimum Additional Application Amount, including switches	Rs.1000/- (plus in multiple of Re.1) Minimum additional application amount for switch ins – Rs. 1000/- and any amount thereafter.
SIP Amount	DURING NEW FUND OFFER PERIOD/ DURING ONGOING OFFER PERIOD: · Daily, Weekly, Fortnightly, Monthly SIP\$: Rs. 1000/- (plus in multiple of Re. 1/-) Minimum installments: 6 · Quarterly SIP\$: Rs. 5,000/- (plus in multiple of Re. 1/-) Minimum installments – 4 \$The applicability of the minimum amount of installment mentioned is at the time of registration only
Benchmark	Nifty Pharma TRI
Listing	Being an open ended scheme, the Units of the Scheme will not be listed on any stock exchange, at present.
Fund Manager Details	Kayzad Eghlim and Nishit Patel


The above list is illustrative and not exhaustive, there are several other opportunities that may give rise to special situations.

The information contained herein is solely for private circulation for reading / understanding of registered Mutual Fund Distributors and should not be circulated to investors/prospective investors.

This scheme is suitable for investors who are seeking*:

- Long term wealth creation solution
- An index fund that seeks to track returns by investing in a basket of Nifty Pharma Index stocks and aims to achieve returns of the stated index, subject to tracking error.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.



Investors understand that their principal will be at Very High risk

#It may be noted that the scheme risk-o-meter specified above is based on the internal assessment of scheme characteristics and may vary post NFO, when the actual investments are made. The same shall be updated in accordance with provisions of SEBI circular dated October 5, 2020 on Product labelling in mutual fund schemes on ongoing basis.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Disclaimer: All figures and data given in the document are dated unless stated otherwise. In the preparation of the material contained in this document, the AMC has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the AMC and/or its affiliates and which may have been made available to the AMC and/or to its affiliates. Information gathered and material used in this document is believed to be from reliable sources. The AMC however does not warrant the accuracy, reasonableness and / or completeness of any information. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions, that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc. The AMC (including its affiliates), the Mutual Fund, the trust and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on this material. Investors are advised to consult their own legal, tax and financial advisors to determine possible tax, legal and other financial implications or consequences of subscribing to the units of ICICI Prudential Mutual Fund.

Disclaimer of NSE Indices Limited (NSE Indices):

The Product(s) are not sponsored, endorsed, sold or promoted by NSE Indices Limited ("NSE Indices"). NSE Indices does not make any representation or warranty, express or implied, to the owners of the Product(s) or any member of the public regarding the advisability of investing in securities generally or in the Product(s) particularly or the ability of the Nifty Auto Index to track general stock market performance in India. The relationship of NSE Indices to the Issuer is only in respect of the licensing of certain trademarks and trade names of its Index which is determined, composed and calculated by NSE Indices without regard to the Issuer or the Product(s). NSE Indices does not have any obligation to take the needs of the Issuer or the owners of the Product(s) into consideration in determining, composing or calculating the Nifty Auto Index. NSE Indices is not responsible for or has participated in the determination of the timing of, prices at, or quantities of the Product(s) to be issued or in the determination or calculation of the equation by which the Product(s) is to be converted into cash. NSE Indices has no obligation or liability in connection with the administration, marketing or trading of the Product(s).

NSE Indices do not guarantee the accuracy and/or the completeness of the Nifty Auto Index or any data included therein and they shall have no liability for any errors, omissions, or interruptions therein. NSE Indices does not make any warranty, express or implied, as to results to be obtained by the Issuer, owners of the product(s), or any other person or entity from the use of the Nifty Auto Index or any data included therein. NSE Indices makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the index or any data included therein. Without limiting any of the foregoing, NSE Indices expressly disclaims any and all liability for any damages or losses arising out of or related to the Products, including any and all direct, special, punitive, indirect, or consequential damages (including lost profits), even if notified of the possibility of such damages.

The information contained herein is only for the purpose of information and not for distribution and do not constitute an offer to buy or sell or solicitation of any offer to buy or sell any securities or financial instruments in the United States of America ("US") and/or Canada or for the benefit of US persons (being persons falling within the definition of the term "US Person" under the US Securities Act, 1933, as amended) or persons residing in Canada.